Date of birth: May 17, 1982
Education and training:
14/JUL/2001: Graduation at the High School, Liceo Classico “L. Galvani”, Bologna (vote: 100/100).
11/JUN/2007: Degree in Medicine and Surgery, University of Bologna. Thesis Title: “Study of gene expression profiling of colorectal liver metastases”. Result: 110/100 cum laude
MAR/2008 – OCT/2012: Specialization training program in Medical Oncology at Department of Hematology and Oncological Sciences “L.A. Seragnoli”, S.Orsola-Malpighi Hospital, University of Bologna
30/OCT/2012: Specialization in Medical Oncology at Department of Hematology and Oncological Sciences “L.A. Seragnoli”, S.Orsola-Malpighi Hospital, University of Bologna. Thesis title: “Genomic Analysis of KIT/PDGFRA Wild-type (WT) gastrointestinal stromal tumors (GIST) with next generation sequencing approach”. Vote: 70/70 cum laude
Position
From March 2022: Senior assistant professor at Department of Medical and Surgical Sciences (DIMEC)- DIMEC - Academic discipline: MED/06 Medical Oncology
From March 2020 to March 2022: Medical Oncologist (Medical Oncology Unit - IRCCS University Hospital of Bologna, Via Albertoni 15, 40138 Bologna)
From 1/AUG/2014 to 31/07/2019: Researcher at Department of Specialized, Experimental and Diagnostic Medicine of the University of Bologna – Istituto L.A. Seragnoli, Policlinico S.Orsola-Malpighi, via Massarenti 9, 40138, Bologna. Project title: “Biology and treatment of rare tumors on a molecular basis as a clinical model in medical oncology”
From April 2017: National Scientific Qualification for associated professor.
Membership
Member of ERN-EURACAN (IRCCS Azienda Ospedaliero-Universitaria di Bologna)
Membrer of GISTSTUDYGROUP of Bologna (www.giststudygroup.it)
Member of SARCOMASTUDYGROUP of Bologna (www.sarcomastudygroup.it)
Referent of WT GIST Unit of Bologna
Member of multidisciplinary team of GIST/SOFT TISSUE SARCOMAS P
Member of multidisciplinary team GROT (Gruppo di Oncologia Tiroidea)
Member of multidisciplinary team of adrenal diseases
Award
14-15/MAY/2013 (Prague): award for the best case study presented at ARCHEOLOGIST Summit 2013.
Clinical trials:
Principal Investigator according to Good Clinical Practice in:
- METROPHOLYS: Ciclofosfamide metronomica vs Doxorubicina in pazienti anziani con sarcoma dei tessuti molli in stadio avanzatoStudio clinico controllato, randomizzato, in aperto
- ISG-ARTICLE: Studio randomizzato di fase II sull’attività della Trabectedina vs Gemcitabina in pazienti con leiomiosarcoma metastatico o localmente avanzato pretrattati con chemioterapia convenzionale
- SALUDO: Studio randomizzato, controllato, in aperto, di fase IIb/III su lurbinectedina in combinazione con doxorubicina rispetto a doxorubicina in monoterapia come trattamento di prima linea in pazienti con leiomiosarcoma metastatico
- MK-6482-015: A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α related Genetic Alterations
- STRATEGIST-3: A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
Sub-Investigator, Co-Investigator
- ISG-TOMAS2: Studio di fase 2 randomizzato sulla combinazione di trabectedin + olaparib vs. trabectedin in pazienti affetti da sarcoma non operabile avanzato o metastatico dopo il fallimento delle linee di trattamento standard
- DCC-2618-03-002: A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib
- BLU-285-1303: “Studio internazionale di fase 3, multicentrico, in aperto, randomizzato per valutare BLU-285 rispetto a regorafenib in pazienti con tumore stromale gastrointestinale (GIST) non resecabile o metastatico localmente avanzato”
- CrenoGIST: A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene
- Novartis CSTI571X2103: A dose-finding phase Ib multicenter study of imatinib in combination with the oral phosphatidyl-inositol 3- kinase (PI3K) inhibitor BYL719 in patients with gastrointestinal stromal tumor (GIST) who failed prior therapy with imatinib and sunitinib
- TROBS: Trabectedin in soft tissue sarcoma. A retrospective observational analysis.
- ALDOXORUBIN-P3-STS-01: Studio multicentrico, randomizzato, in aperto, di Fase 3 per valutare l’efficacia e la sicurezza di aldoxorubicina rispetto alla scelta dello sperimentatore in soggetti con sarcomi dei tessuti molli metastatici, localmente avanzati o non resecabili, recidivati o refrattari dopo trattamento chemioterapico non adiuvante
- BAY 73-4506/14874: “Studio randomizzato, in doppio cieco, controllato verso placebo, di fase III su regorafenib più la migliore terapia di supporto verso placebo più la migliore terapia di supporto in soggetti con tumori stromali gastrointestinali metastatici e/o non resecabili (GIST) la cui malattia è progredita nonostante un trattamento precedente con almeno imatinib e sunitinib”
- PEAK: a phase 3 randomized, open-label, multicenter clinical study of CGT9486+sunitinib vs sunitinib in subjects with locally advanced, unresectable, or metastatic gastrointestinal stromal tumors
- INSIGHT: An International, Phase 3, Randomized, Multicenter, Open label Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) with KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated with Imatinib
Research field:
- Gastrointestinal tumors
- Soft Tissue Sarcomas
- Thyroid cancer
Peer-reviewed publications
Orcid: https://orcid.org/my-orcid?orcid=0000-0002-2103-1960
